VivoSeq
Gastroenterology

Gastroesophageal Junction

0

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Gastroesophageal Junction is an early-stage landscape with 0 programs across 3 companies. The most active players are Radiation Therapy Oncology Group, Enzon Pharmaceuticals, Inc., Takeda.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

59/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group

0 programs

PreclinicalE

Enzon Pharmaceuticals, Inc.

0 programs

PreclinicalTakeda logo

Takeda

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed13 · 48%
Terminated8 · 30%
Unknown status2 · 7%
Active, not recruiting2 · 7%
Withdrawn1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction
Recruiting·—·Phase 2·NCT05865132·30 enrolled
Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
Active, not recruiting·—·Phase 2·NCT05480384·1 enrolled
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Active, not recruiting·—·Phase 1/2·NCT04921904·8 enrolled
Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00891878·12 enrolled
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00938470·73 enrolled
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Completed·Radiation Therapy Oncology Group logoRadiation Therapy Oncology Group·Phase 2·NCT00069953·43 enrolled
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00054457·46 enrolled
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
Completed·National Cancer Institute (NCI)·Phase 2·NCT00062374·55 enrolled
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Completed·WWake Forest University Health Sciences·Phase 1·NCT01561014·9 enrolled
Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00022139·56 enrolled
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Completed·MMayo Clinic·Phase 1/2·NCT02730546·31 enrolled
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
Completed·—·Phase 2·NCT00601705·61 enrolled
[68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer
Completed·—·Phase 2·NCT05898854·20 enrolled
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00107341·37 enrolled
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Completed·National Cancer Institute (NCI)·Phase 2·NCT00061932·41 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)